Recent

% | $
Quotes you view appear here for quick access.

Neostem, Inc. Message Board

  • bob_flemings bob_flemings Oct 22, 2013 9:35 AM Flag

    apples to oranges

    NeoStem has been at the center of a storm surrounding the results of a CADUCEUS study. The study noted that stem cell treatment was "safe and effective in decreasing scar size and in increasing viable tissue," but "did not lead to any significant changes from baseline to 1 year in end-diastolic and end-systolic volumes, cardiac output, or stroke volume - which also was evident at 6 months."

    A post seen on Seeking Alpha ran with this statement and painted all stem cells with the same brush, which is a far cry from the truth. The CADUCEUS trial used cardiosphere-derived stem cells or CDCs, whereas AMR-001 uses stem cells derived from bone marrow, a disparity that NeoStem CEO, Robin Smith, likened to "comparing apples and oranges.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
NBS
2.250.00(0.00%)Jun 5 3:59 PMEDT